Robin Feldman

Robin Feldman, an expert in drug patents and generics from the University of California Hastings College of Law, discusses the tactics employed by pharmaceutical companies to reduce competition from generic drugs. Topics include the Hatch-Waxman Act, weak patents, pay for delay settlements, evasion of price controls, complexities of drug pricing, and challenges in replacing branded drugs with ineffective capsules.

Robin Feldman, a law professor and expert in pharmaceutical law, dives into the complexities of drug pricing and regulation. She discusses how the current legal framework incentivizes drug companies to cling to monopolies, often leading to high costs for consumers. Feldman critiques the role of pharmacy benefit managers in manipulating prices and hindering transparency. The conversation also highlights the need for systemic reforms in patent laws to prioritize real innovation over minor modifications that merely extend profitability.